Hess Midstream Partners LP (HESM) signals a pivotal shift towards robust free cash flow generation, forecasting a 40% drop in capital expenditures for 2026 as its core system build-out concludes. Despite near-term weather headwinds, strong minimum volume commitments underpin financial targets through 2028.
Wells Fargo's board has approved a 28% compensation increase for CEO Charlie Scharf, bringing his total package to $40 million for the past year. The move comes as the bank marks a pivotal turnaround, with major federal penalties lifted and its transformation under Scharf's leadership cited as justification for the raise.
Tree Accountancy strengthens its regional footprint by absorbing Pomegranate Consulting's UK portfolio and key staff, marking its second strategic acquisition in three years as it expands advisory services.
Facing pressure from both investors and regulators, banks and wealth managers are turning to pass-through voting mechanisms to reclaim shareholder influence and align stewardship with client values, even within passively managed funds.
A volatile January has underscored a stark shift for investors: political shocks emanating from Washington now pose a greater threat to portfolios than traditional economic or earnings concerns, reshaping risk calculus across global markets.
The Schwab U.S. Dividend Equity ETF (SCHD) offers investors a balanced approach to generating income, targeting financially robust companies with a history of growing dividends. We examine its strategy, performance, and role in a portfolio.
As the 2027 deadline for Swift's Case Management standard approaches, banks face a strategic inflection point. Early adopters of native processing are poised to unlock operational resilience and revenue growth, while laggards risk entrenched inefficiency and competitive decline.
Aptiv reported record fourth-quarter revenue of $5.2 billion, a 3% increase, as the automotive technology leader prepares to spin off its Electrical Distribution Systems business as the independent company Versagen on April 1, 2026.
Piper Sandler raises its price target on ImmunityBio, citing a near 700% surge in Anktiva sales and promising interim data from the QUILT trials that could support a major label expansion by 2027.
A suspected human smuggler with a prior conviction was shot by federal agents near the Arizona-Mexico border after allegedly firing at a CBP helicopter and agents during a foot pursuit, according to law enforcement officials.
A 68-year-old Cincinnati woman and her two adult children perished in a fast-moving house fire last month, with officials describing the conditions as 'not survivable.'
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Aptiv PLC sees mixed but upwardly revised price targets from major analysts, with Piper Sandler upgrading the auto tech supplier to Overweight and naming it a top pick for 2026, citing its pragmatic strategy and attractive valuation.
Despite recent guidance revisions, Mobileye Global retains strong buy ratings from analysts who see significant upside potential, as the company positions 2026 for a strategic transition in the autonomous driving sector.
Russia's premier cryptocurrency miner, BitRiver, faces insolvency proceedings as its CEO is placed under house arrest, marking a dramatic fall for a firm already crippled by international sanctions and mounting legal disputes.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.
Clear Street downgrades Janux Therapeutics (JANX) to Hold, slashing its price target amid concerns over a lack of durability data for its lead candidate JANX007 and rising competitive pressures, despite a recent major collaboration deal with Bristol Myers Squibb.
Seventeen-year-old Hailey Buzbee vanished after leaving her Vermillion home in early January. Authorities now believe she is deceased and have arrested a man she met through online gaming, though murder charges have not yet been filed.
